Search Results - "Palomero, L"

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Disease networks identify specific conditions and pleiotropy influencing multimorbidity in the general population by Amell, A., Roso-Llorach, A., Palomero, L., Cuadras, D., Galván-Femenía, I., Serra-Musach, J., Comellas, F., de Cid, R., Pujana, M. A., Violán, C.

    Published in Scientific reports (29-10-2018)
    “…Multimorbidity is an emerging topic in public health policy because of its increasing prevalence and socio-economic impact. However, the age- and…”
    Get full text
    Journal Article Publication
  2. 2
  3. 3
  4. 4

    2013PThe SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent by Ruggero, K, Martinez, A, Chen, X, Bizri, R El, Farran, S, Palomero, L, Piulats, J M, Villanueva, A, Pujana, M A, Aytes, A

    Published in Annals of oncology (01-10-2019)
    “…Abstract Background Resistance to androgen receptor signaling is arguably the principal hallmark of lethal prostate cancer. Several mechanisms account for this…”
    Get full text
    Journal Article
  5. 5
  6. 6

    2013P - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent by Ruggero, K., Martinez, A., Chen, X., Bizri, R El, Farran, S., Palomero, L., Piulats, J.M., Villanueva, A., Pujana, M.A., Aytes, A.

    Published in Annals of oncology (01-10-2019)
    “…Resistance to androgen receptor signaling is arguably the principal hallmark of lethal prostate cancer. Several mechanisms account for this resistance,…”
    Get full text
    Journal Article
  7. 7

    Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition by Mateo, F, Arenas, E J, Aguilar, H, Serra-Musach, J, de Garibay, G Ruiz, Boni, J, Maicas, M, Du, S, Iorio, F, Herranz-Ors, C, Islam, A, Prado, X, Llorente, A, Petit, A, Vidal, A, Català, I, Soler, T, Venturas, G, Rojo-Sebastian, A, Serra, H, Cuadras, D, Blanco, I, Lozano, J, Canals, F, Sieuwerts, A M, de Weerd, V, Look, M P, Puertas, S, García, N, Perkins, A S, Bonifaci, N, Skowron, M, Gómez-Baldó, L, Hernández, V, Martínez-Aranda, A, Martínez-Iniesta, M, Serrat, X, Cerón, J, Brunet, J, Barretina, M P, Gil, M, Falo, C, Fernández, A, Morilla, I, Pernas, S, Plà, M J, Andreu, X, Seguí, M A, Ballester, R, Castellà, E, Nellist, M, Morales, S, Valls, J, Velasco, A, Matias-Guiu, X, Figueras, A, Sánchez-Mut, J V, Sánchez-Céspedes, M, Cordero, A, Gómez-Miragaya, J, Palomero, L, Gómez, A, Gajewski, T F, Cohen, E E W, Jesiotr, M, Bodnar, L, Quintela-Fandino, M, López-Bigas, N, Valdés-Mas, R, Puente, X S, Viñals, F, Casanovas, O, Graupera, M, Hernández-Losa, J, Ramón y Cajal, S, García-Alonso, L, Saez-Rodriguez, J, Esteller, M, Sierra, A, Martín-Martín, N, Matheu, A, Carracedo, A, González-Suárez, E, Nanjundan, M, Cortés, J, Lázaro, C, Odero, M D, Martens, J W M, Moreno-Bueno, G, Barcellos-Hoff, M H, Villanueva, A, Gomis, R R, Pujana, M A

    Published in Oncogene (11-05-2017)
    “…Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive…”
    Get full text
    Journal Article
  8. 8